Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Last trade$2.14
Day change$0.00 (0.00%)
Day range$2.10 – $2.23
Volume21,932
Market cap$7M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.22M
Price / earnings
—
Price / book
1.53×
Price / sales
6.2×
EV / sales
-0.02×
EV / EBITDA
0×
Profitability
Earnings per share
-$6.64
Return on assets
-186.33%
Return on equity
-475.33%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.12×
Quick ratio
1.12×
Cash ratio
0.99×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$18.18M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LGVN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$115K
$287K
$398K
$365K
$137K
$316K
$381K
$603K
Cost of revenue
$44K
$105K
$134K
$108K
$12K
$170K
$106K
$73K
Gross profit
$71K
$182K
$264K
$257K
$125K
$146K
$275K
$530K
Selling, general and administrative
$3.31M
$3.16M
$2.72M
$2.94M
$3.58M
$2.59M
$2.94M
$2.82M
Research and development
$3.96M
$3.19M
$2.32M
$2.72M
$3.85M
$2.95M
$2.52M
$1.99M
Total operating expenses
$7.27M
$6.35M
$5.04M
$5.66M
$7.44M
$5.54M
$5.46M
$4.81M
Operating income
-$7.2M
-$6.17M
-$4.78M
-$5.4M
-$7.31M
-$5.4M
-$5.18M
-$4.28M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$6.14M
-$6.07M
-$4.74M
-$5.44M
-$7.22M
-$5.03M
-$5.01M
-$4.08M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.14M
-$6.07M
-$4.74M
-$5.44M
-$7.22M
-$5.03M
-$5.01M
-$4.08M
Net income attributable to common shareholders
-$6.14M
-$6.07M
-$4.74M
-$5.44M
-$7.22M
-$5.03M
-$5.01M
-$4.08M
EBITDA
-$6.97M
-$5.95M
-$4.52M
-$5.12M
-$7.05M
-$5.13M
-$4.76M
-$4.04M
Basic earnings per share
-$1.91
-$1.90
-$1.90
-$2.48
-$3.93
-$3.30
-$3.40
-$2.72
Diluted earnings per share
-$1.91
-$1.90
-$1.90
-$2.48
-$3.93
-$3.30
-$3.40
-$2.72
Recent news
Company coverage with links to the original publishers.
Longeveron Inc. (NASDAQ: LGVN) announced a 1-for-10 reverse stock split effective August 26, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split will reduce outstanding Class A shares from approximately 30.4 million to 3.0 million shares. The company is approaching milestones across four stem cell therapy development programs and appointed Nirav Jhaveri as Chief Financial Officer.
The longevity biotech market is expanding rapidly, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034. Multiple companies are advancing cell and gene therapies targeting age-related diseases: Lineage Cell Therapeutics is developing islet therapy for Type 1 diabetes, Ocugen reported 46% lesion reduction in age-related macular degeneration, Vertex is advancing stem cell-derived islet therapy toward regulatory submissions, and Longeveron published positive Phase 2b data for age-related frailty treatment.
Avaí Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in-a-Box® encapsulation technology. The cell therapy sector is rapidly expanding, with the global market projected to grow from $10.4 billion to over $45 billion by 2035.
The global cell therapy market is projected to surpass $8.2 billion in 2026, with CAR T-cell therapy expanding at 18% annually. Several companies are advancing manufacturing milestones and clinical breakthroughs: Avaí Bio initiated Master Cell Bank production for α-Klotho anti-aging therapy; FibroBiologics secured a patent for fibroblast cell therapy for osteoporosis; Fate Therapeutics achieved same-day hospital discharge for off-the-shelf CAR T-cell patients; Mesoblast presented favorable survival data for Ryoncil® in graft-versus-host disease; and Longeveron published Phase 2b results showing stem cell therapy improved physical condition in age-related frailty patients.
Longeveron Inc. completed a public offering of 5,882,354 Class A common stock and short-term warrants, raising approximately $5 million, with potential additional proceeds of $12.5 million from warrant exercises. The company plans to use funds for clinical development of laromestrocel targeting various medical conditions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.